{"slug":"aml","tag":"aml","variants":["aml"],"description":"No description yet","count":8,"kinds":{"person":7,"biomarker":1},"related":[{"slug":"flt3","tag":"flt3","shared":2},{"slug":"menin","tag":"menin","shared":2},{"slug":"targeted-therapy","tag":"targeted-therapy","shared":2},{"slug":"venetoclax","tag":"venetoclax","shared":2},{"slug":"australia","tag":"australia","shared":1},{"slug":"biomarker","tag":"biomarker","shared":1},{"slug":"classification","tag":"classification","shared":1},{"slug":"cooperative-group","tag":"cooperative-group","shared":1},{"slug":"early-phase","tag":"early-phase","shared":1},{"slug":"guidelines","tag":"guidelines","shared":1},{"slug":"idh","tag":"idh","shared":1},{"slug":"trialist","tag":"trialist","shared":1}],"records":[{"id":"courtney-dinardo","kind":"person","name":"Courtney D. DiNardo","route":"/people/courtney-dinardo/","tldr":"Led VIALE-A, which made venetoclax plus azacitidine the standard for older patients with acute myeloid leukaemia."},{"id":"richard-stone","kind":"person","name":"Richard M. Stone","route":"/people/richard-stone/","tldr":"Led RATIFY, the trial that made midostaurin the first targeted therapy added to induction chemotherapy for AML."},{"id":"alexander-perl","kind":"person","name":"Alexander E. Perl","route":"/people/alexander-perl/","tldr":"Led ADMIRAL, which made gilteritinib the standard for relapsed FLT3-mutant AML."},{"id":"hartmut-dohner","kind":"person","name":"Hartmut Döhner","route":"/people/hartmut-dohner/","tldr":"Leads the European LeukemiaNet classification that defines how AML is diagnosed and risk-stratified worldwide."},{"id":"eytan-stein","kind":"person","name":"Eytan M. Stein","route":"/people/eytan-stein/","tldr":"Led the enasidenib and revumenib trials that brought IDH2 and menin inhibitors to acute leukaemia."},{"id":"ghayas-issa","kind":"person","name":"Ghayas C. Issa","route":"/people/ghayas-issa/","tldr":"First author of the revumenib trial that created the menin inhibitor class for acute leukaemia."},{"id":"andrew-wei","kind":"person","name":"Andrew H. Wei","route":"/people/andrew-wei/","tldr":"Australian haematologist who led VIALE-C and QUAZAR AML-001, advancing venetoclax and oral azacitidine maintenance in AML."},{"id":"npm1-mutation","kind":"biomarker","name":"NPM1 mutation","route":"/biomarkers/npm1-mutation/","tldr":"NPM1 mutations, found in about a third of adult acute myeloid leukaemias, misplace the nucleophosmin protein into the cytoplasm. They mean a better outlook without FLT3-ITD, a sensitive MRD marker, and since 2025 a targeted menin inhibitor."}]}